fbpx Skip to main content

It is essential that the lack of racial and ethnic diversity in prostate cancer clinical trials be addressed, in order to improve health disparities seen amongst these racial/ethnic minority patient populations. This study suggests that population-based cancer registries could be used as a source for the recruitment in minority patients in order to overcome problems with inclusion of diverse patient populations in clinical trial research.

In January of 2019 the Assembly Bill (AB2325) went into effect in the state of California. This bill mandated the electronic reporting of structured data elements to the California Cancer Registry (CCR) from pathologists diagnosing cancer in patients. Using information electronically gathered from CCR the investigators of the study employed ECA or “rapid case ascertainment” to screen through pathology reports from cancer patient diagnosis.

The research group’s goal for this study was to demonstrate that leveraging structured electronic pathology or e-path data reporting to a population-based cancer registry for the recruitment of men with high risk prostate cancer to clinical research, would prove feasible and acceptable. This was a nonrandomized study among patients with new pathologic diagnosis of high-risk prostate cancer. This study tested the utility of an online clinical trial matching tool called Trial Library; an internet-based clinical trial matching website used in combination with e-path to improve matching of underrepresented prostate cancer patients into clinical trials at time of diagnosis.

They were successful in demonstrating that e-path could be linked with an online clinical trial matching tool such as Trial Library. The researchers state that future studies should prioritize recruitment from reporting facilities that serve more racially/ethnically diverse patient populations in order to bring about improvements in cancer clinical trial disparities.

You May Also Like::  Significant Inequities in Diagnostic Imaging for Prostate Cancer

Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More